About Excision Medical

Excision Medical is developing a Leaflet Excision System that enables targeted removal of aortic valve leaflets to mitigate risks associated with redo transcatheter aortic valve replacement (TAVR) procedures. This technology addresses the limitations of current leaflet modification methods, enhancing patient safety and improving procedural outcomes for those with bioprosthetic valve failure.

```xml <problem> Redo transcatheter aortic valve replacement (TAVR) procedures are often complicated by the presence of the existing failed valve, which can lead to acute obstruction of the coronary artery ostia and other hazards. Current methods for modifying leaflets before redo TAVR are limited and can be time-consuming. There are currently no commercially available methods for meaningful leaflet modification involving complete leaflet excision. </problem> <solution> Excision Medical is developing a Leaflet Excision System designed to enable targeted removal of aortic valve leaflets, mitigating risks associated with redo TAVR procedures. The system allows physicians to target and excise one or more aortic valve leaflets while considering the hemodynamic needs of patients. Leaflet removal is key to mitigating the risk of coronary artery ostia obstruction and debulking the existing valve prior to the redo TAVR, which may also offer additional benefits to the performance of the new valve. The system is designed to integrate into the workflow of TAVR procedures. </solution> <features> - Stýri™ Steering Catheters for precise navigation and positioning. - Viking™ RF Excision Catheter for targeted leaflet removal. - HemoShield™ Temporary Valve to maintain hemodynamic stability during the procedure. - Patent-pending leaflet modification technology. </features> <target_audience> The primary users are physicians specializing in structural heart disease, specifically those performing TAVR and redo TAVR procedures. </target_audience> ```

What does Excision Medical do?

Where is Excision Medical located?

Excision Medical is based in Malvern, Canada.

When was Excision Medical founded?

Excision Medical was founded in 2020.

How much funding has Excision Medical raised?

Excision Medical has raised 18190000.

Location

Malvern, Canada

Founded

2020

Funding

18190000

Employees

15 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Excision Medical

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

excisionmed.com 100+

Crunchbase

Founded 2020 – Malvern, Canada

Funding

Estimated Funding

$10M+

Team (15+)

No team information available.

Company Description

Problem

Redo transcatheter aortic valve replacement (TAVR) procedures are often complicated by the presence of the existing failed valve, which can lead to acute obstruction of the coronary artery ostia and other hazards. Current methods for modifying leaflets before redo TAVR are limited and can be time-consuming. There are currently no commercially available methods for meaningful leaflet modification involving complete leaflet excision.

Solution

Excision Medical is developing a Leaflet Excision System designed to enable targeted removal of aortic valve leaflets, mitigating risks associated with redo TAVR procedures. The system allows physicians to target and excise one or more aortic valve leaflets while considering the hemodynamic needs of patients. Leaflet removal is key to mitigating the risk of coronary artery ostia obstruction and debulking the existing valve prior to the redo TAVR, which may also offer additional benefits to the performance of the new valve. The system is designed to integrate into the workflow of TAVR procedures.

Features

Stýri™ Steering Catheters for precise navigation and positioning.

Viking™ RF Excision Catheter for targeted leaflet removal.

HemoShield™ Temporary Valve to maintain hemodynamic stability during the procedure.

Patent-pending leaflet modification technology.

Target Audience

The primary users are physicians specializing in structural heart disease, specifically those performing TAVR and redo TAVR procedures.